Current Affairs - Science - Discussion

Coartem is the first-ever malaria drug that has been approved for use specifically in newborns and very young children, marking a significant milestone in the fight against malaria. Developed by Novartis, this drug received approval from Swiss authorities and aims to reduce the high mortality rate of malaria among infants, particularly in Africa, where the majority of malaria-related deaths occur. In 2023 alone, malaria caused over half a million deaths worldwide, highlighting the critical need for targeted treatments like Coartem to protect the most vulnerable populations.